Pergolide protects SH-SY5Y cells against neurodegeneration induced by H2O2
Abstract
We found that pergolide, a dopamine D1/D2 receptor agonist used in the clinical therapy of Parkinson's disease, protects SH-SY5Y neuroblastoma cells from cell death induced by a brief pulse (15 min) of 1 mM H(2)O(2). Neuroprotection was found when pergolide was added to the culture medium either simultaneously with (EC(50)=60 nM) or 2 h before (EC(50)=40 nM) H(2)O(2) treatment. These effects were not blocked by different dopamine receptor antagonists. Our data suggest that pergolide, independently of dopamine receptor stimulation, may interfere with the early phases of the oxidative stress-induced neurotoxic process.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The human neuroblastoma SH-SY5Y is among the most used cell lines, a subclone of the parental neuronal line SK-N-SH, which originated in 1970 from a biopsy metastatic tumor.
“The human neuroblastoma SH-SY5Y is among the most used cell lines [131,136,137,138,139,140,141,142], a subclone of a parental neuronal line SK-N-SH, which originated in 1970 from a biopsy metastatic tumor.”
From Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation (2022) · cites this paper as [141]
Cites
Tietze, F. (1969) · Analytical Biochemistry · doi:10.1016/0003-2697(69)90064-5 · Cited by 6,077 · see citing works
Jones, K. H., & Senft, J. A. (1985) · Journal of Histochemistry & Cytochemistry · doi:10.1177/33.1.2578146 · Cited by 1,104 · see citing works
Prospects for new restorative and neuroprotective treatments in Parkinson's disease
Dunnett, S. B., & Björklund, A. (1999) · Nature · doi:10.1038/399a032 · Cited by 539 · see citing works
Invited Review Free radicals and the pathobiology of brain dopamine systems
Cadet, J. L., & Brannock, C. (1998) · Neurochemistry International · doi:10.1016/s0197-0186(97)00031-4 · Cited by 499 · see citing works
Kitamura, Y., Kosaka, T., Kakimura, J., et al. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.6.1046 · Cited by 181 · see citing works
Bignami, G. F. (1999) · Nature · doi:10.1038/19899 · Cited by 163 · see citing works
Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro
Ogawa, N., Tanaka, K.-I., Asanuma, M., Kawai, M., Masumizu, T., Kohno, M., & Mori, A. (1994) · Brain Research · doi:10.1016/0006-8993(94)90969-5 · Cited by 160 · see citing works
Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats
Felten, D. L., Felten, S. Y., Fuller, R. W., Romano, T. D., Smalstig, E. B., Wong, D. T., & Clemens, J. A. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90048-3 · Cited by 150 · see citing works
Gassen, M., Gross, A., & Youdim, M. B. H. (1998) · Movement Disorders · doi:10.1002/mds.870130208 · Cited by 134 · see citing works
Antioxidant Properties of Bromocriptine, a Dopamine Agonist
Yoshikawa, T., Minamiyama, Y., Naito, Y., & Kondo, M. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62031034.x · Cited by 118 · see citing works
Fuller, R. W., Clemens, J. A., Kornfeld, E. C., et al. (1979) · Life Sciences · doi:10.1016/0024-3205(79)90334-5 · Cited by 104 · see citing works
Pergolide monotherapy in the treatment of early PD
Barone, P., Bravi, D., Bermejo‐Pareja, F., Marconi, R., Kulisevsky, J., Malagù, S., Weiser, R., Rost, N. S., & the Pergolide Monotherapy Study Group (1999) · Neurology · doi:10.1212/wnl.53.3.573 · Cited by 102 · see citing works
Self-citationAttenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole
Carvey, P. M., Pieri, S., & Ling, Z. D. (1997) · Journal of Neural Transmission · doi:10.1007/bf01273182 · Cited by 97 · see citing works
Itano, Y., & Nomura, Y. (1995) · Brain Research · doi:10.1016/0006-8993(95)01120-x · Cited by 74 · see citing works
Gómez‐Vargas, M., Nishibayashi‐Asanuma, S., Asanuma, M., et al. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01521-7 · Cited by 59 · see citing works
Free radical scavengers: chemical concepts and clinical relevance
Gassen, M., & Youdim, M. B. H. (1999) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6360-3_13 · Cited by 55 · see citing works
Farooqui, S. M. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00520-6 · Cited by 53 · see citing works
Characterization of tau proteins in human neuroblastoma SH-SY5Y cell line
Uberti, D. L., Rizzini, C., Spano, P., & Memo, M. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00715-5 · Cited by 51 · see citing works
Self-citationA culture model for age‐related human neurofibrillary pathology
Cole, G. M., Wu, K., & Timiras, P. S. (1985) · International Journal of Developmental Neuroscience · doi:10.1016/0736-5748(85)90016-4 · Cited by 29 · see citing works
Pergolide: Long-Term Use in Parkinson's Disease
Ahlskog, J. E., & Muenter, M. D. (1988) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)64912-x · Cited by 27 · see citing works
Activation of adenylate cyclase in rat striatum by an ergoline dopamine agonist, pergolide.
Wong, D. T., & Reid, L. R. (1980) · PubMed · Cited by 20 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Sharifi-Rad, J., Rapposelli, S., Sestito, S., Herrera-Bravo, J., Arancibia-Diaz, A., Salazar, L. A., Yeskaliyeva, B., Beyatli, A., Leyva-Gómez, G., González-Contreras, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091515 · Cited by 125 · see citing works
- Authors
- Uberti, D., Piccioni, L., Colzi, A., Bravi, D., Canonico, P. L., & Memo, M.
- Affiliations
- University of Brescia (IT)
- Eli Lilly (Italy) (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Corresponding author
- Memo, Maurizio
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2002-01
- Volume
- 434
- Issue
- 1-2
- Pages
- 17-20
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2075332170
- Cited by
- 49
- References
- 21
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 4 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 2
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- pergolide, neuroprotection, SH-SY5Y cells, hydrogen peroxide, oxidative stress, neurotoxicity, Parkinson's disease, cell death, dopamine antagonists
- MeSH terms
- Humans, Hydrogen Peroxide, Neuroblastoma, Pergolide, Tumor Cells, Cultured, Apoptosis, Oxidative Stress, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
